How Long Until Wegovy Works? A Realistic Semaglutide 2.4 mg Timeline

The short answer: days for appetite, months for the full effect

If you are asking "how long until Wegovy works," the honest answer depends on what you mean by working. Many people first notice a change in appetite and satiety — feeling less hungry and getting full sooner — within the first days to few weeks of starting. That early signal is not the same as weight loss; it is the drug beginning to influence how much you want to eat.

Measurable change on the scale builds more slowly, over weeks, and continues to accumulate as the dose is stepped up. The pivotal trial of semaglutide 2.4 mg, STEP-1, ran for 68 weeks, and in obesity trials of this class the maximal effect was reached late — roughly the 60-to-72-week mark. So the realistic mental model is a long, gradual build measured in months, not a fast result measured in days. If you expect a switch to flip, you will misread a normal, working ramp as failure.

Why the dose is raised gradually (and why that is the point)

Wegovy is not started at its full strength. The FDA-Wegovy label uses a gradual titration schedule that begins at a low starting dose and steps up in stages over several months until the maintenance dose is reached. This slow escalation exists for a reason: it gives your body time to adapt and helps limit the nausea, and other gastrointestinal side effects that are most common when a dose first increases.

This is also why the timeline feels long. During the early weeks you may be on a dose that is intentionally sub-therapeutic for weight — its job is to build tolerance, not to deliver the full effect. Trying to rush the schedule tends to trade a slightly faster start for worse side effects, and prescribers generally hold or slow the step-up if tolerance is poor. Reading the titration months as "nothing is happening" is one of the most common ways people misjudge this drug.

A realistic week-by-week expectation arc (qualitative)

First days to first few weeks: this is the appetite phase. You may notice reduced hunger, earlier fullness, and less interest in large portions. Side effects like mild nausea are also most likely around a new dose. The scale may barely move yet, and that is expected — the drug is establishing its effect and you are still early in titration.

Across the following weeks and months: as the dose steps up per the schedule, appetite effects tend to be more consistent and weight change becomes measurable and cumulative rather than sudden. Because STEP-1 ran 68 weeks and the class reaches its maximal effect late, the most useful checkpoint is a trend over months, not a reading over days. Progress that looks slow week to week can still be a healthy, working trajectory when you zoom out — which is exactly how the pivotal trial measured it.

What "working" means for Wegovy's approved use

Wegovy is FDA-approved for chronic weight management, and "chronic" is the key word. Success for this indication is sustained progress toward a weight goal over the long term, alongside a reduced-calorie diet and increased physical activity — the same conditions under which STEP-1 was run. It is not designed or approved as a short crash intervention, and judging it on a two-week timescale misrepresents the approved use.

This framing also matters because the effect is tied to continued treatment. Trials in this drug class that studied stopping treatment — for example the tirzepatide maintenance trial SURMOUNT-4 — found that weight tends to return after the medication is withdrawn. The practical implication for Wegovy: "working" is a maintained trajectory over months on therapy, and any decision to start, continue, or stop belongs with your prescriber, not a countdown clock.

Wegovy vs. Ozempic: same molecule, different approvals

Wegovy and Ozempic contain the same active molecule, semaglutide, which is why they are so often confused. The difference is the FDA-approved use. Wegovy (semaglutide 2.4 mg) is approved for chronic weight management, per the FDA-Wegovy label. Ozempic is approved for type 2 diabetes — so using Ozempic for weight loss is off-label.

This distinction is not just paperwork; it defines which product's timeline and titration schedule actually apply to a weight-management goal. If your objective is weight management, the on-label semaglutide product is Wegovy, and its FDA-Wegovy titration schedule is the one this page describes. The same on-label-versus-off-label split appears elsewhere in the class: Zepbound (tirzepatide) is approved for chronic weight management, while Mounjaro (the same tirzepatide molecule) is approved for type 2 diabetes. You can compare the approved weight-management options on our medications and brands pages.

Red flags: when to contact your prescriber instead of waiting

A gradual, unremarkable ramp is normal. Some things are not, and they are a reason to call a clinician rather than sit out the timeline. Contact your prescriber promptly if you have severe or persistent nausea, vomiting, or inability to keep fluids down; severe abdominal pain (especially pain that radiates to the back), which can signal pancreatitis; signs of gallbladder problems; symptoms of dehydration; or any allergic-type reaction.

Also reach out if side effects are bad enough that you are tempted to skip doses or stop on your own, if you are pregnant or planning pregnancy, or if you take other medications and are unsure about interactions. Separately, the FDA has warned about unapproved, compounded, and counterfeit GLP-1 products sold for weight loss (see the FDA GLP-1 alert); the timeline and safety profile on this page apply to the FDA-approved Wegovy product, not to unapproved versions. When in doubt, the prescriber who knows your history is the right call — not the internet.

Frequently asked questions

How soon will I feel Wegovy working?

Many people notice appetite and satiety changes — less hunger, feeling full sooner — within the first days to few weeks. That early signal is different from weight loss, which builds more gradually over weeks and months as the dose is stepped up.

How long until Wegovy reaches its full effect?

It is a slow build measured in months, not days. The pivotal STEP-1 trial ran 68 weeks, and obesity trials in this class reached their maximal effect late, roughly the 60-to-72-week range. Expect a trend over many months rather than a fast result.

Why does Wegovy start at a low dose?

The FDA-Wegovy label uses a gradual titration schedule that steps the dose up over several months. Starting low and escalating slowly helps your body adapt and limits nausea and other gastrointestinal side effects that are most common when a dose first increases.

Is Wegovy the same as Ozempic, and do they work on the same timeline?

Both contain the same molecule, semaglutide, but their FDA approvals differ. Wegovy is approved for chronic weight management; Ozempic is approved for type 2 diabetes, so using Ozempic for weight loss is off-label. For a weight-management goal, Wegovy is the on-label semaglutide product and its titration schedule is the relevant one.

What happens if I stop Wegovy once it is working?

The effect is tied to continued treatment. Trials in this drug class that studied stopping — such as the tirzepatide SURMOUNT-4 maintenance trial — found weight tends to return after the medication is withdrawn. Any decision to start, continue, or stop should be made with your prescriber.

When should I contact a prescriber instead of waiting for it to work?

Reach out for severe or persistent vomiting, severe abdominal pain (especially radiating to the back), signs of gallbladder problems or dehydration, allergic-type reactions, or side effects bad enough that you want to skip doses. Also avoid unapproved or compounded GLP-1 products, which the FDA has warned about.

Primary sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med, 2021.
2. FDA label: Wegovy (semaglutide 2.4 mg) — chronic weight management.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med, 2022.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA, 2024.
5. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.